Scarica l'app Stockscreener
161.28
1.89%
2.99
Dopo l'orario di chiusura:
161.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$158.29
Aprire:
$159.21
Volume 24 ore:
723.32K
Relative Volume:
0.50
Capitalizzazione di mercato:
$11.17B
Reddito:
$2.90B
Utile/perdita netta:
$302.80M
Rapporto P/E:
37.54
EPS:
4.2965
Flusso di cassa netto:
$387.80M
1 W Prestazione:
-1.95%
1M Prestazione:
+7.01%
6M Prestazione:
-44.20%
1 anno Prestazione:
-45.77%
Intervallo 1D:
$158.30
$161.82
Intervallo di 1 settimana:
$153.64
$164.40
Portata 52W:
$138.79
$354.88
Insulet Corp Stock (PODD) Company Profile
Nome
Insulet Corp
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
161.28 | 11.17B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corp Borsa (PODD) Ultime notizie
PODD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - GlobeNewswire Inc.
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
PODD Shareholder Alert: Insulet Corporation Securities - GlobeNewswire
Stifel cuts Insulet stock price target on valuation, keeps buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Insulet stock reflects steady diabetes tech demand as investors watch U.S. growth - AD HOC NEWS
Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47% - Yahoo Finance
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation LawsuitPODD - Morningstar
PODD Shareholder Alert: Insulet Corporation Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Insulet focuses on diabetes technology growth. Business model supports recurring revenue - Ad-hoc-news.de
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026PODD - Morningstar
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
PODD Maintained by Citigroup -- Price Target Raised to $172 - GuruFocus
Insulet (PODD) Launches Omnipod 5 In Spain, Is The Upside Already Priced In? - simplywall.st
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut? - Yahoo Finance
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain - Yahoo Finance
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit - PR Newswire
Form 4 Insulet Corporation For: 7 July By Investing.com - Investing.com Nigeria
Insulet Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Insulet (PODD) director updates award to 151 deferred stock units - Stock Titan
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Why Insulet (PODD) Could Beat Earnings Estimates Again - Yahoo Finance
Insulet launches Omnipod 5 in Spain - MedTech Dive
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
PODD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - Morningstar
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target - Insider Monkey
FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports - Benzinga
Class action lawsuit filed against Insulet over alleged false statements causing investor losses - Pluang
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm - Barchart.com
Insulet Misled Investors on Manufacturing Procedures, Suit Says - Bloomberg Law News
PODD Expands Omnipod 5 Launch to Spain, Enhancing Diabetes Care - GuruFocus
Insulet launches Omnipod 5 insulin system in Spain - Investing.com
Insulet launches Omnipod 5 insulin system in Spain By Investing.com - Investing.com South Africa
Insulet brings tubeless diabetes tech to Spain with Omnipod 5 launch - Stock Titan
VERI DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Veritone, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
PODDInsulet Corp Latest SEC Filings - Finviz
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Class action lawsuit filed against Insulet over alleged false statements on product safety. - Pluang
Bernstein SocGen cuts Insulet stock price target on valuation concerns - Investing.com
Insulet faces shareholder lawsuit over alleged false safety claims and product issues. - Pluang
Class action filed against Insulet over alleged product safety and disclosure issues, stock drops follow. - Pluang
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation - GlobeNewswire
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD) - TMX Newsfile
FDA Alerts on Insulet (PODD) Device Safety Concerns - GuruFocus
Insulet (PODD) Faces Class I Recall of Omnipod Insulin Pump Syst - GuruFocus
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG - Seeking Alpha
Class action lawsuit filed against Insulet over defective insulin delivery systems and stock drops. - Pluang
Insulet Corp Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):